Pharmaceutical

Ultrasonic processing produces uniform nanocarriers such as nanocrystals, nanoemulsions, and liposomes, and performs cell disruption (lysis) to extract active ingredients from biomass. These steps help overcome the poor water solubility that limits many drug compounds.

Up to 40% of available bioactive substances, and up to 70% of those in development, have poor water solubility, which lowers bioavailability and delays onset. Formulating them as nanocrystals, nanoemulsions, or liposomes increases dissolution and absorption, improving therapeutic performance.

Liposomes are lipid vesicles that encapsulate active ingredients for targeted delivery. High-intensity ultrasonic cavitation reduces and homogenises lipid structures into uniform liposomes, providing a simple, reproducible production method on lab, bench, and industrial scales.

Yes. The strong shear forces generated by ultrasonic cavitation rupture yeast, bacterial, and plant cell walls, releasing recombinant proteins, medicinal oils, and other bioactive substances for downstream processing.

Industrial Sonomechanics processors use patented Barbell Horn Ultrasonic Technology (BHUT), which preserves the required amplitude as equipment size increases, so processes validated in the lab transfer to production with reproducible, high-quality results.